Cargando…
Updated Review on Clinically-Relevant Properties of Delafloxacin
The extensive use of fluoroquinolones has been consequently accompanied by the emergence of bacterial resistance, which triggers the necessity to discover new compounds. Delafloxacin is a brand-new anionic non-zwitterionic fluoroquinolone with some structural particularities that give it attractive...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451745/ https://www.ncbi.nlm.nih.gov/pubmed/37627661 http://dx.doi.org/10.3390/antibiotics12081241 |
_version_ | 1785095492652236800 |
---|---|
author | Turban, Adrien Guérin, François Dinh, Aurélien Cattoir, Vincent |
author_facet | Turban, Adrien Guérin, François Dinh, Aurélien Cattoir, Vincent |
author_sort | Turban, Adrien |
collection | PubMed |
description | The extensive use of fluoroquinolones has been consequently accompanied by the emergence of bacterial resistance, which triggers the necessity to discover new compounds. Delafloxacin is a brand-new anionic non-zwitterionic fluoroquinolone with some structural particularities that give it attractive proprieties: high activity under acidic conditions, greater in vitro activity against Gram-positive bacteria—even those showing resistance to currently-used fluoroquinolones—and nearly equivalent affinity for both type-II topoisomerases (i.e., DNA gyrase and topoisomerase IV). During phases II and III clinical trials, delafloxacin showed non-inferiority compared to standard-of-care therapy in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, which resulted in its approval in 2017 by the Food and Drug Administration for indications. Thanks to its overall good tolerance, its broad-spectrum in vitro activity, and its ease of use, it could represent a promising molecule for the treatment of bacterial infections. |
format | Online Article Text |
id | pubmed-10451745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104517452023-08-26 Updated Review on Clinically-Relevant Properties of Delafloxacin Turban, Adrien Guérin, François Dinh, Aurélien Cattoir, Vincent Antibiotics (Basel) Review The extensive use of fluoroquinolones has been consequently accompanied by the emergence of bacterial resistance, which triggers the necessity to discover new compounds. Delafloxacin is a brand-new anionic non-zwitterionic fluoroquinolone with some structural particularities that give it attractive proprieties: high activity under acidic conditions, greater in vitro activity against Gram-positive bacteria—even those showing resistance to currently-used fluoroquinolones—and nearly equivalent affinity for both type-II topoisomerases (i.e., DNA gyrase and topoisomerase IV). During phases II and III clinical trials, delafloxacin showed non-inferiority compared to standard-of-care therapy in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, which resulted in its approval in 2017 by the Food and Drug Administration for indications. Thanks to its overall good tolerance, its broad-spectrum in vitro activity, and its ease of use, it could represent a promising molecule for the treatment of bacterial infections. MDPI 2023-07-28 /pmc/articles/PMC10451745/ /pubmed/37627661 http://dx.doi.org/10.3390/antibiotics12081241 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Turban, Adrien Guérin, François Dinh, Aurélien Cattoir, Vincent Updated Review on Clinically-Relevant Properties of Delafloxacin |
title | Updated Review on Clinically-Relevant Properties of Delafloxacin |
title_full | Updated Review on Clinically-Relevant Properties of Delafloxacin |
title_fullStr | Updated Review on Clinically-Relevant Properties of Delafloxacin |
title_full_unstemmed | Updated Review on Clinically-Relevant Properties of Delafloxacin |
title_short | Updated Review on Clinically-Relevant Properties of Delafloxacin |
title_sort | updated review on clinically-relevant properties of delafloxacin |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451745/ https://www.ncbi.nlm.nih.gov/pubmed/37627661 http://dx.doi.org/10.3390/antibiotics12081241 |
work_keys_str_mv | AT turbanadrien updatedreviewonclinicallyrelevantpropertiesofdelafloxacin AT guerinfrancois updatedreviewonclinicallyrelevantpropertiesofdelafloxacin AT dinhaurelien updatedreviewonclinicallyrelevantpropertiesofdelafloxacin AT cattoirvincent updatedreviewonclinicallyrelevantpropertiesofdelafloxacin |